Press
Releases
Press Releases
AVROBIO Presents Clinician Experience with FAB-GT Clinical Trial and Updated Safety Data for Investigational Gene Therapies in Fabry Disease and Gaucher Disease Type 1
Safety data updates for Phase 1 and 2 Fabry disease clinical trials and Phase 1/2 Gaucher disease type 1 clinical trial show no adverse events or serious adverse events related to drug product CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 24, 2021-- AVROBIO, Inc.
Nov 24, 2021
AVROBIO to Present at Two Upcoming Investor Conferences in November
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 9, 2021-- AVROBIO, Inc . (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that members of its senior management team are scheduled to participate in two upcoming
Nov 09, 2021
AVROBIO to Present Clinical and Preclinical Data at the 14th ICIEM Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 8, 2021-- AVROBIO, Inc . (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that it will present safety data from its clinical trials in Fabry disease and Gaucher
Nov 08, 2021
AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 5, 2021-- AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted a non-statutory stock option for the purchase of up to
Nov 05, 2021
AVROBIO Reports Third Quarter 2021 Financial Results and Provides Business Update
Provided comprehensive safety update on AVROBIO’s lentiviral gene therapy platform and programs at ESGCT 2021 Received FDA feedback on CMC requirements for anticipated Fabry disease registration trial; registration study initiation anticipated for mid-2022 Cash runway extended into fourth quarter
Nov 04, 2021
AVROBIO Receives Rare Pediatric Disease Designation from the U.S. FDA for AVR-RD-05, a Gene Therapy for Mucopolysaccharidosis Type II (MPSII) or Hunter Syndrome
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 3, 2021-- AVROBIO, Inc . (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease
Nov 03, 2021
AVROBIO Announces the Appointment of Essra Ridha, M.D., MRCP, FFPM, as Chief Medical Officer
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 26, 2021-- AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a vision to free people from a lifetime of genetic disease, today announced the appointment of Essra Ridha , M.D., MRCP, FFPM, as chief medical officer. Dr.
Oct 26, 2021
AVROBIO to Present at the Jefferies Virtual Gene Therapy/Editing Summit
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 20, 2021-- AVROBIO, Inc . (NASDAQ:AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that members of its senior management team will present at the Jefferies Virtual Gene
Oct 20, 2021
AVROBIO Reports New Interim Safety Data Across Investigational Gene Therapies for Fabry and Gaucher Disease Type 1
No adverse events or serious adverse events related to drug product in 14 patients treated in Phase 1 and 2 Fabry disease trials and Phase 1/2 Gaucher disease trial Post-gene therapy administration safety data out 4½ years for first patient dosed AVROBIO leads way with new industry-leading
Oct 19, 2021
AVROBIO to Present New Clinical and Preclinical Data Across Multiple Programs at the ESGCT 28th Annual Congress
New safety data to be reported from clinical trials in Fabry disease and Gaucher disease type 1 CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 6, 2021-- AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today
Oct 06, 2021
Displaying 1 - 10 of 35